Objective: Despite numerous treatments for epilepsy, over 30% of patients remain resistant to available antiseizure drugs (ASDs). Thus, there is a strong need for more effective ASDs for these individuals. Early ASD discovery has historically relied on acute in vivo seizure models (maximal electroshock, subcutaneous pentylenetetrazol, 6 Hz), which lack the pathophysiology that defines chronic epilepsy. Etiologically relevant rodent models of pharmacoresistant epilepsy exist (eg, phenytoin (PHT)-and lamotrigine (LTG)-resistant amygdala-kindled rat and focal kainic acid mouse), but these models are resource-and labor-intensive and thus unsuitable for frontline ASD discovery. Methods: We adapted the LTG-resistant amygdala-kindled rat protocol to the 60 Hz corneal-kindled mouse (CKM) to develop a medium-throughput model of pharmacoresistant chronic seizures. Male CF-1 mice were administered either vehicle (VEH; 0.5% methylcellulose) or LTG (8.5 mg/kg, ip) 30 minutes prior to each twice-daily corneal stimulation until mice achieved kindling criterion. Prototype ASDs were then evaluated in fully kindled mice. Compounds with specific mechanisms of action of interest to epilepsy (fluoxetine, minocycline, and celecoxib) were also evaluated. Results: LTG did not modify kindling acquisition. A challenge dose of 17 mg/kg (ip) LTG did not block the secondarily generalized kindled seizure in LTGkindled mice (mean seizure score [MSS] AE standard error of the mean: 5.67 AE 0.14), whereas VEH-treated mice were sensitive (MSS: 2.25 AE 0.30); confirming LTG-resistance. LTG-resistant CKM were also resistant to carbamazepine, retigabine, and valproic acid at doses that significantly reduced MSS in VEH-treated kindled mice. Fluoxetine, minocycline, and celecoxib were ineffective at the doses tested in either kindled cohort. Finally, the behavioral phenotype of LTG-resistant CKM was also characterized. CKM demonstrated exacerbated hyperexcitability and increased anxiety-like behavior in an open field relative to sham-kindled mice regardless of LTG sensitivity. Significance: The pharmacoresistant LTG-resistant CKM provides an etiologically relevant moderate-throughput platform that is suitable for early compound discovery before advancing to more resource-intensive models of epilepsy.
intact rodents. Rodents with chronic and/or spontaneous seizures are certainly available in the drug discovery armamentarium, 7 but these models do not always exhibit a discernable pharmacoresistance. 10, 11 Models of chronic seizures are also often highly labor-and resource-intensive and thus are not suitable for the early evaluation of large chemical libraries for moderate-to high-throughput drug discovery. Two in vivo models were prioritized for investigational drug differentiation in the National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP) in 2015 for their pharmacoresistant seizure profile 8, 12 : the focal intrahippocampal kainic acid mouse model of hippocampal paroxysmal discharges and the lamotrigine (LTG)-resistant amygdalakindled rat. However, these models are frankly not suitable for frontline ASD identification. The focal kainic acid mouse model requires stereotaxic surgery, long-duration video-electroencephalography (EEG) recordings, social isolation for long periods of time to accommodate the video-EEG recording, [13] [14] [15] [16] and is defined by infrequent spontaneous convulsive seizures. 14 The LTG-resistant amygdala-kindled rat also requires stereotaxic surgical implantation and social isolation 17 ; nonetheless the very fact that 400-600 g rats are undesirable for any early drug discovery endeavor because of the amount of test article required. Therefore, there is a significant unmet need for etiologically relevant models of pharmacoresistant seizures that are suitable for early moderate-to high-throughput drug screening. To address this demand for etiologically relevant models of pharmacoresistant seizures for early drug discovery, we adapted the protocol of the LTG-resistant amygdala-kindled rat 18 to the well-characterized 60 Hz corneal-kindled mouse (CKM). 10, 19 The 60 Hz CKM is a moderate-throughput model of secondarily generalized focal seizures that is technically feasible and minimally invasive. 19 This model is frequently used for frontline drug evaluations and exhibits a pharmacology consistent with the hippocampal-kindled rat, 10 albeit minimal pharmacoresistance. 20 The NINDS ETSP even prioritized the 60 Hz CKM for the initial identification of anticonvulsant efficacy in 2015. 8 CKM do not require surgical intervention, are suitable for repeated drug
Key Points
• Pharmacoresistance to available antiseizure drugs (ASDs) is a problem for >30% of the over 65 million people worldwide with epilepsy
• ASD discovery has commonly relied on the identification of efficacy in acute seizure models in neurologically intact rodents (eg, maximal electroshock test)
• The lamotrigine-resistant corneal kindled mouse is suitable for frontline ASD discovery before drugs are differentiated in more resource-intensive models evaluations, 8, 21 and can be socially housed throughout the duration of their use, 19 thereby minimizing any confounds of chronic stress. 22 Moreover, the 60 Hz CKM exhibits behavioral comorbidities 21, 23 and pathophysiology 24 reminiscent of human epilepsy 25 ; for example, memory deficits 21, 23 and neuroinflammation. 24 We presently describe the pharmacological and behavioral characterization of the LTG-pharmacoresistant 60 Hz CKM. We further define the pharmacological profile of this model with several compounds with mechanisms of action of interest for epilepsy, 8 including the anti-inflammatory agents, minocycline and celecoxib, and the serotonergic agent, fluoxetine.
The results described herein demonstrate that the LTG-resistant CKM is wholly suitable for frontline ASD screening before a molecule of interest is advanced to more resource-and labor-intensive models of pharmacoresistant epilepsy.
| METHODS

| Animals
All animal experimentation was approved by the University of Washington Institutional Animal Care and Use Committee. CF-1 male mice (15-25 g at day 0, approximately 4-to 5-weeks-old; Charles River Laboratories) were housed 5 mice/cage in a temperature-controlled vivarium on a 14:10 light/dark cycle. Animals were provided free access to irradiated chow (Picolab 5053) and filtered water, except during behavioral testing. Mice were given at minimum 1 hour to acclimate to the procedure room prior to all testing. All drug testing was conducted by an experimenter who was blinded to treatment.
| Corneal kindling and drug screening
Mice were randomized to 2 kindling groups: sham-kindling or corneal-kindling. Corneal-kindling groups (n = 30/treatment groups) received either intraperitoneal (ip) 0.5% methylcellulose vehicle (MC; Sigma Aldrich, M0430) or LTG (8.5 mg/kg; Table 1 ) injection 30 minutes before each twice-daily corneal stimulation (60 Hz, 3 seconds, 3 mA stimulation). Mice were stimulated twice daily until they reached a criterion of 5 consecutive Racine stage 5 seizures (facial clonus and head nodding progressing to forelimb clonus, and finally rearing and falling accompanied by a generalized clonic seizure; see Video S1), according to our established protocols. 8, 10, 21 This dose of LTG was based on the median effective dose of LTG in the mouse MES test. 21 Twice-daily stimulations continued until each mouse had achieved the criterion of 5 consecutive stage 5 seizures, whereby it was considered "fully kindled." Fully kindled mice were then stimulated every other day until all other mice within the group reached the criterion of 5 consecutive stage 5 seizures. 8 Any mouse not achieving the fully kindled state by 17 days post initiation was not included in any subsequent testing. Testing of investigational compounds commenced 5-7 days after the last corneal stimulation necessary to achieve kindling criterion within the treatment group. 8, 10, 21 Mice were stimulated the day before drug testing to ensure the stability of the stage 5 seizure; those mice who did not present with a baseline stage 5 seizure were excluded from testing, consistent with our established protocols. 8, 10 Animals were scored during the acute drug administration studies using a modified Racine scale (stage 1-6) because of the observation of more severe and phenotypically different generalized seizures (Videos S1 and S2). In addition to the Racine stages 1-5 seizures, 8, 10 stage 6 seizures were defined as prolonged, severe "popcorn" seizures (Video S2). Each kindled mouse was allowed at least 48 hours between tests to "washout" any investigational compound after acute drug testing. Finally, a sham kindling group (n = 5) had the corneal electrodes applied but no stimulation delivered.
| Behavioral assessment of anxiety-like behavior and hyperexcitability
A cohort of CKM from both treatment groups (n = 20/ group), and sham-kindled mice (n = 5), underwent behavioral assessment of general hyperexcitability during the kindling acquisition process and immediately after achieving kindling criterion based on a hyperexcitability test adapted from a rat post-pilocarpine model. 26 The mice were also tested shortly after the final kindling stimulation (day 21) in an automated open-field (OF) test of anxietylike behavior. 27 Hyperexcitability testing was performed prior to the morning corneal stimulation, once at the beginning of the kindling process (day 7) and once after mice had reached the aforementioned, fully kindled state (day 21). Testing was conducted within each mouse's home cage with cage mates in a separate, empty cage. Hyperexcitability of rodents with chronic epilepsy can be determined with the sum of 4 tests (approach-response test, touch-response test, snap test, and pick-up test) according to previously defined scoring criteria. 26, 28 OF testing was performed once at the conclusion of the kindling process in a nonorientating acrylic glass chamber (40L 9 40W 9 30H cm) equipped with infrared sensors to detect animal movement for 10 minutes. 29 Testing was conducted 1 hour following the hyperexcitability testing (day 21) with a 1-hour period of reacclimatization. Animal placement within the chambers was randomized by the computer program Accuscan (Omnitech Electronics, Dartmouth, Canada). Cages were wiped clean between animals with water and fecal boli removed.
| Pharmacological assessment
Mice were challenged with LTG (17 mg/kg, ip) after a 5-day washout following kindling acquisition to determine LTG sensitivity. Fully kindled mice were then tested for their sensitivity to other ASDs and mechanistic compounds over the following months (Table 1) . At minimum, each drug and dose were tested in n = 6 mice/group (group sizes listed in Figure 2 legend). Mice were tested at maximum twice/week: baseline testing on Monday, anticonvulsant testing on Tuesday, washout period on Wednesday, baseline testing on Thursday, and anticonvulsant testing on Friday ( Figure 1D ).
| Statistical analysis
Kindling acquisition curves and daily body weight were compared by repeated-measure analysis of variance (ANOVA). Seizure scores and OF data were compared between treatment groups by 2-way ANOVA with Tukey's and Dunnett's post hoc tests, respectively. Hyperexcitability testing pre-and postkindling was compared for each session by 1-way ANOVA with Tukey's post hoc tests. Survival during kindling acquisition was compared by the Kaplan-Meier test. All statistical analysis was conducted by F I G U R E 1 Male CF-1 mice were divided into 2 kindling groups: sham-(n = 5) and corneal-kindled cohorts (n = 30). Cornealkindled mice were treated (ip) with either 0.5% MC (VEH; n = 29) or 8.5 mg/kg LTG (n = 30) 30 min prior to each twice-daily corneal stimulation session. A, Body weight was not significantly affected by kindling or treatment during the kindling process. B, Administration of twice-daily LTG during the kindling acquisition process did not significantly delay acquisition of the fully kindled state. C, Administration of LTG during kindling acquisition did not significantly modify survival during the kindling process. D, Upon completion of corneal kindling, animals that achieved the fully kindled state were enrolled for subsequent evaluations of acute anticonvulsant efficacy with prototype ASDs or mechanistically distinct compounds GraphPad Prism 6.0 software (GraphPad, La Jolla, CA, USA), with P < .05 considered statistically significant.
| RESULTS
| Body weight changes and kindling acquisition
One vehicle (VEH)-treated mouse unexplainably died on day 1, leaving n = 29 VEH-treated mice to complete kindling. Body weight changes during the kindling period were not significantly impacted by either corneal kindling or twice-daily ip administration of VEH or LTG ( Figure 1A ). All mice gained weight in an age-dependent manner (F (10,590) = 4.41, P < .0001), which was unaffected by kindling (F (2,59) = 1.18, P > .3). There was also no significant kindling 9 time effect on body weight (F (20, 590) = 0.983, P > .7). Twice-daily administration of LTG did not significantly modify kindling acquisition ( Figure 1B ; F (1,33) = 0.63, P > .43), consistent with the LTG-resistant amygdala-kindled rat. 18 As expected, twice-daily corneal kindling significantly increased seizure score (effect of time, F (25,825) = 189.4, P < .0001). Sham-kindled mice did not display seizures ( Figure 1B ). Corneal kindling was itself associated with mortality ( Figure 1C ), consistent with previous reports. 30 In total, 5 of 29 (17.2%) VEH-treated mice died during the kindling period, which was unobserved overnight. One of 30 (3.3%) LTG-treated mice died during the kindling period; however, this mortality difference was not significant (Fisher's exact test, P = .10). Kaplan-Meier analysis also did not demonstrate any disease-modifying effects of LTG on kindling ( Figure 1C ; v 2 = 3.53, P > .06). Twenty-two of 24 surviving (91.7%) VEH-treated mice achieved the kindling criterion and 27 of 29 (93.1%) LTG-kindled mice achieved the criterion; all fully kindled mice were enrolled for subsequent pharmacological profiling.
| Mice kindled in the presence of lowdose LTG are resistant to escalating doses of LTG
The pharmacosensitivity to escalating doses of LTG (17 mg/kg and 50 mg/kg, ip) was first confirmed in a subset of fully kindled VEH-(n = 12 and n = 8, respectively) and LTG-kindled mice (n = 17 and n = 8, respectively; Figure 2A ). There was a statistically significant kindling group 9 LTG dose interaction (F (2,74) = 23.67, P < .0001), with LTG-kindled mice being highly refractory to escalating doses of LTG (Figure 2A ). Figure 2C ) at the doses tested demonstrated similar degrees of efficacy in both VEHand LTG-kindled mice (eg, no effect of kindling or kindling 9 treatment interaction). There was an effect of LEV treatment on MSS in both VEH-and LTG-kindled mice (Figure 2B ; F (3,66) = 13.5, P < .0001); no significant differences in efficacy were observed between kindling groups (F (1,66) = .079, P > .7). DZP treatment significantly reduced MSS (F (2,54) = 152.5, P < .0001). Similar effects were noted in both kindling groups ( Figure 2C ; F (1, 54) = 2.373, P > .1). DZP induced significant reductions in MSS in both VEH-and LTG-kindled groups (F (2,54) = 152.5, P < .0001). DZP at 1 and 2 mg/kg reduced MSS in VEH-kindled mice to 1.75 AE 0.33 and 2.2 AE 0.74, respectively. In the LTGkindled group, these doses of DZP reduced MSS to 1.85 AE 0.40 and 1.0 AE 0.19, respectively. Thus, the effect of DZP on MSS at the doses tested was not notably different between the VEH-and LTG-kindling groups. As shown in Figure 2D -H, varying degrees of efficacy and potency were observed among the other prototype ASDs.
As shown in Figure 2D , phenobarbital (PB) dose-dependently reduced MSS in both treatment groups (F (3,69) = 11.8, P < .0001); 30 mg/kg (3.3 AE 0.53, P = .024) and 45 mg/kg (2.9 AE 0.61, P = .0017). In contrast, only the high PB dose (45 mg/kg) significantly reduced MSS in LTG-resistant CKM (3.1 AE 0.67, P = .01). VEH-kindled mice generally responded better to PB than LTG-kindled mice (effect of kindling, F (1,69) = 4.072, P = .0475).
As shown in Figure 2E , VEH-kindled mice were sensitive to carbamazepine (CBZ) in a dose-dependent manner (kindling group 9 treatment interaction, F (3,74) = 6.50, P = .0006). CBZ significantly reduced MSS at 20 mg/kg KONEVAL ET AL. demonstrate varied sensitivity to subsequent acute pharmacological intervention with prototype ASDs. A, Escalating doses of LTG are effective in VEH-(n = 12-13/dose), but not LTG-kindled mice (n = 18-20/dose). B, Escalating doses of LEV are effective in both VEH-(n = 8-15/dose) and LTG-kindled mice (n = 15/dose). C, Escalating doses of DZP are effective in both VEH-(n = 6-8/dose) and LTG-kindled mice (n = 8/dose). D, Escalating doses of PB are effective in both VEH-(n = 6-9/dose) and LTG-kindled mice (n = 7-9/dose). E, Escalating doses of CBZ are effective in VEH-(n = 6-9/dose), but not LTG-kindled mice (n = 7-10/dose). F, Escalating doses of VPA are effective in VEH-(n = 6-8/dose), but not LTG-kindled mice (n = 8-9/dose). G, Escalating doses of RTG are effective in VEH-(n = 6-7/dose), but not LTG-kindled mice (n = 6-8/dose). H, Escalating doses of PHT are ineffective in both VEH-(n = 7-14/dose) and LTG-kindled mice (n = 14-16/dose). *Indicates significantly different from same kindling group baseline MSS, P < .05.
#
Indicates significantly different from VEH-kindled group of same drug dose, P < .05 (3.1 AE 0.40; P < .0001) and 40 mg/kg (3.0 AE 0.63; P < .0001) in VEH-kindled mice. Neither dose of CBZ reduced the MSS of LTG-kindled mice ( Figure 2E 
that CBZ was also ineffective in LTG-kindled mice relative to VEH-kindled mice treated with these same doses (P = .0005 and P = .0174, respectively).
Valproic acid (VPA) produced a significant effect of kindling (F (1,70) = 13.85, P < .0001), effect of treatment (F (3,70) = 27.9, P < .0001), and trend for a kindling 9 treatment interaction ( Figure 2F; F (3,70) = 2.67, P = .054). As shown in Figure 2E , VPA dose-dependently reduced MSS in VEH-kindled mice: 150 mg/kg-2.5 AE 0.56 (P = .002) and 300 mg/kg-1.1 AE 0.58 (P < .0001). A reduction in VPA potency was observed in LTG-kindled mice. For example, the highest dose (300 mg/kg) of VPA decreased the MSS of LTG-kindled mice to the same degree as that seen with 150 mg/kg in VEH-kindled mice (2.6 AE 0.53, P = .0004).
The Kv 7.2/7.3 activator, retigabine (RTG), produced a main effect of kindling (F (1, 51) = 5.844, P < .019) and of treatment on MSS (F (2, 51) = 17.12, P < .0001), and was also associated with a trend for kindling 9 treatment interaction ( Figure 2G ; F (2,51) = 3.13, P = .0522). In VEHkindled mice, RTG dose-dependently reduced MSS relative to baseline: 5 mg/kg-5.0 AE 0.0 (P > .9) and 10 mg/kg-2.8 AE 0.73 (P = .0001). Conversely, RTG did not reduce MSS in LTG-kindled mice: 5 mg/kg-5.3 AE 0.16 (P > .99) and 10 mg/kg-4.3 AE 0.49 (P > .3). At the highest dose tested (10 mg/kg), RTG decreased the MSS; however, the magnitude of effect was less in LTG-kindled vs VEH-kindled mice (P = .049). Thus, RTG was ineffective in LTG-kindled mice at the doses tested relative to VEH-kindled mice.
Unlike the other ASDs tested, PHT did not robustly reduce MSS in either kindling group. As shown in Figure 2H , PHT was nonetheless associated with an effect of kindling (F (1,96) = 12.35, P < .0001) and of PHT treatment (F (3,96) = 3.045, P = .033). At the highest dose tested, that is, 40 mg/kg, PHT did not modify the MSS of VEH-kindled mice. Of interest, this same dose produced an increase in MSS when administered to LTG-kindled mice (MSS of 4.4 AE 0.65 in VEH-kindled vs MSS of 5.9 AE 0.08 for LTG-kindled, respectively; P = .017). Moreover, LTGkindled mice demonstrated severe seizure worsening at this highest dose of PHT (ie, popcorn seizures).
| Mechanistic compounds do not acutely reduce MSS in LTG-resistant mice
In an effort to determine whether anti-inflammatory treatments may acutely suppress seizures in this model, as has previously been reported in the 6 Hz model of pharmacoresistant acute partial seizures, 31 we evaluated whether MSS of VEH-and LTG-kindled mice would be modified by the Post hoc tests revealed that LTG-kindled mice showed exacerbated seizure score relative to VEH-kindled mice (P = .0055). B, Regardless of dose, CXB was ineffective in both VEH-(n = 8/dose) and LTG-kindled mice (n = 7-8/dose). C, FXT (25 mg/kg) significantly reduces MSS in VEH-(n = 8), but not LTG-kindled mice (n = 8). *Indicates significantly different from same kindling group baseline MSS, P < .05.
#
Indicates significantly different from VEH-kindled group of same drug dose, P < .05 anti-inflammatory antibiotic, minocycline (MIN; Figure 3A) , and the nonsteroidal anti-inflammatory drug, celecoxib (CXB). The MSS of VEH-kindled mice in the presence of 25 mg/kg MIN was 4.25 AE 0.75. Of interest, this same dose of MIN exacerbated the MSS in LTGkindled mice (5.4 AE 0.18), an effect reflective of the treatment 9 kindling interaction (F (1,39) = 8.81, P = .005). Escalating doses of MIN were not evaluated due to the significant morbidity and mortality noted in pilot studies with doses >100 mg/kg (not shown). The nonsteroidal antiinflammatory drug CXB was without effect on MSS of either kindling group at the two doses tested; that is, 2 and 4 mg/kg ( Figure 3B ). Thus further dose-response studies were not pursued.
Finally, treatment with 25 mg/kg fluoxetine (FXT) produced a treatment 9 kindling interaction (F (1,42) = 17.3, P < .0002). This dose was selected on the basis of prior reports that showed that 25 mg/kg FXT increases MES threshold in male Swiss mice. 32 The MSS of VEH-kindled mice following FXT treatment was 4.4 AE 0.58; P = .003. In contrast, this same dose of FXT resulted in an increase (worsening) of MSS when given to LTG-kindled mice (5.6 AE 0.18; P < .02). Whether escalating doses of FXT would lessen the MSS in VEH-kindled mice or further increase the MSS in LTG-resistant CKM remains to be defined.
| Corneal-kindled mice exhibit alterations in behavioral comorbidities irrespective of pharmacosensitivity
To further characterize the behavioral phenotype of LTGresistant CKM, we evaluated their hyperexcitability and anxiety-like behavior in an OF (n = 20/kindling; Figure 4A-G); all mice tested were fully kindled. The hyperexcitability battery is useful to qualitatively evaluate changes in behavior in a noninvasive manner and was conducted during kindling acquisition ("pre-kindling"; day 7 of kindling) and day 21 post-kindling initiation ("post-kindling"). All groups demonstrated similar hyperexcitability during the kindling (or sham-kindling) process ( Figure 4A ; F (2,30) = 0.4488, P > .6). However, only VEH-and LTGtreated mice that achieved the kindling criterion demonstrated sustained elevations in hyperexcitability ( Figure 4B ; F (2,30) = 8.067, P < .002). LTG did not affect hyperexcitability versus VEH-kindled mice at either time point (P > .8).
OF activity was evaluated at the conclusion of kindling acquisition (day 18 post-initiation). There was no significant difference in total distance traveled within the OF between sham-kindled and CKM of either treatment group ( Figure 4C; F (2,30) = 0.941, P > .4). CKM of both treatment conditions (VEH-and LTG-treated) spent significantly less of the total time within the center of the OF ( Figure 4D ; F (2,30) = 1.21, P = .013), an observation suggestive of an increased anxiety-like behavioral phenotype. Dunnett's post hoc test revealed that both VEH-kindled and LTG-kindled mice spent significantly less of their total exploration time in the OF center (P = .041 and P = .007, respectively). There was no significant difference in the total distance traveled within the OF center between shamkindled and corneal-kindled mice of either treatment group ( Figure 4E; F (2,30) = 0.523, P > .5). Finally, there were no significant differences in the total vertical ( Figure 4F ) or horizontal activity counts ( Figure 4G ) between shamkindled and CKM of either treatment group (vertical: F (2,30) = 1.46, P > .2; horizontal: F (2,30) = 0.717, P > .4).
| DISCUSSION
The pharmacological and behavioral profile of LTG-resistant CKM demonstrates the suitability of this model for medium-throughput frontline screening of potential anticonvulsant drugs before they are advanced to more resourceintensive differentiation models; for example, LTG-resistant kindled rat or focal kainic acid mouse. 12 Low-dose LTG administration during kindling does not modify acquisition of the fully kindled state, but does lead to an LTG-resistant CKM that is also resistant to other ASDs, including CBZ,
Corneal-kindled mice demonstrate exacerbations in behavioral hyperexcitability (A&B) and open field (OF; C-G) activity relative to age-matched sham-kindled mice. A subset of all animals that started the kindling process were included for behavioral analysis (n = 20/group). Only animals that had achieved the fully kindled state were included in this behavioral testing. A, Behavioral hyperexcitability was assessed during the kindling acquisition process ("pre-kindling") and on (B) day 21 post-initiation of the kindling process ("post-kindling"), a time point when all mice had achieved the fully kindled state. There was no statistically significant difference in behavioral hyperexcitability during the "pre-kindling" period between sham-and corneal-kindled mice, regardless of treatment group. There was a significant increase in behavioral hyperexcitability in kindled mice after achieving the fully kindled state (P < .002). C, No significant difference in total distance traveled in an open field was observed between sham-and corneal-kindled mice. D, Kindled mice spent significantly less of their total exploration time in the center of an OF, an effect suggestive of increased anxiety-like behavior. There is no difference between VEH-or LTGkindled mice. *Indicates significantly different from sham-kindling group, P < .05. E, There is no significant difference in the percent of the total distance traveled in the center of an open field between sham-and corneal-kindled mice. F, No significant difference in vertical activity counts between sham-and corneal-kindled mice was noted. G, No significant difference in horizontal activity counts between sham-and corneal-kindled mice was observed VPA, and RTG, consistent with the more labor-intensive LTG-resistant amygdala-kindled rat. 18 As such, the LTGresistant CKM is a pharmacologically valid, moderatethroughput model of pharmacoresistant seizures that is amenable to the early screening of large libraries of investigational compounds for potential use for drug-resistant epilepsy. Drug-refractory epilepsy is likely the result of a complex combination of mechanisms, including modifications of therapeutic targets, 33 changes in multidrug transporters at the blood-brain barrier (BBB), 34 and even failures in medication adherence. 35 Although not the focus of this study, it is possible that the pharmacoresistance observed in the LTG-resistant CKM could arise from modifications in the therapeutic target, that is, sodium channels. In contrast to the LTG-resistant amygdala-kindled rat, 18 the LTG-resistant CKM is resistant to VPA ( Figure 2F ). CBZ, LTG, and VPA exhibit some anticonvulsant effects through sodium channels. 36 PHT shares the same binding site on neuronal sodium channels as LTG and CBZ 37 ; however, PHT did not modify MSS in either VEH-kindled or LTG-kindled mice. This indicates that changes in the therapeutic target alone are insufficient to produce the pharmacoresistance described herein. It is unknown whether RTG is effective in the LTGresistant amygdala-kindled rat, 18 but the fact that RTG shares no known overlap in its mechanism of action with LTG made the present lack of efficacy of RTG surprising. Although RTG was deprioritized for clinical management of epilepsy in 2016, the known antiseizure mechanism of RTG (eg, potassium channel activation) versus LTG (eg, sodium channel inhibition) further indicates that changes in drug target cannot solely account for pharmacoresistance. Changes in efflux transporters at the BBB, for example, P-glycoprotein (PgP), are also hypothesized to contribute to pharamcoresistance. 33 The PgP inhibitor, tariquidar, has even been administered to successfully rescue pharmacoresistance in PB-resistant rats with epilepsy, 34 directly supporting the transporter hypothesis. PB is a PgP substrate, 34, 38 as are LTG, LEV, and PHT. 38 However, LTG-resistant CKM were only modestly less sensitive to PB than VEH-kindled mice, suggesting that PgP overexpression in the context of chronic LTG administration during kindling acquisition may not underlie pharmacoresistance in this model. Furthermore, CBZ is not a substrate for PgP, 38 and thus changes in drug transporters alone cannot explain the presently observed pharmacoresistance.
One clinically relevant finding of this present study is that inappropriate ASD monotherapy early in the disease course can significantly impact later pharmacosensitivity. The LTG-resistant amygdala-kindled rat demonstrates a subsequent pharmacoresistance to CBZ, 18 an effect that is replicated in the LTG-resistant CKM. However, the earlier study in rats did not provide as comprehensive of an evaluation of such a diverse profile of compounds as is described herein, further attesting to the throughput capacity of LTG-resistant CKM. We now demonstrate that LTG monotherapy during epileptogenesis can also drastically modify the trajectory of future pharmacosensitivity, indicating that multimodal factors underlie the development of ASD pharmacoresistance. Kindled rodents have long been used for ASD discovery; however, it is commonly argued that kindling is an insufficient model of epilepsy because these rodents do not typically exhibit spontaneous seizures. Nonetheless, in 2015, the NINDS-sponsored ETSP placed a prominent emphasis on the 60 Hz CKM and LTG-resistant amygdalakindled rat for ASD identification and differentiation, respectively. 8, 12 Indeed, CKM do exhibit pathophysiology consistent with human epilepsy, 25 including cognitive deficits, 23 neuroinflammation, 24 and behavioral disturbances. 39 Both kindling treatment groups (VEH-and LTG-kindled mice) presently demonstrated behavioral hyperexcitability ( Figure 4A ,B) regardless of ASD sensitivity, an effect that was not observed in sham-kindled mice. A history of chronic seizures, regardless of LTG sensitivity, also promoted increased anxiety-like behavior as measured by the extent of time a mouse spent in the center of an OF (Figure 4D) . Although the small group size of the shamkindled mice is a limitation of the present behavioral study, these data support the further detailed evaluation of behavioral phenotypes in VEH-and LTG-kindled mice relative to sham-kindled animals in more sensitive behavioral assays of anxiety-like behavior (eg, elevated plus maze 39 ).
Nonetheless, these data are consistent with findings from Albertini and colleagues in the 6 Hz CKM 39 and support the conclusion that kindled rodents are a clinically useful model of epilepsy for ASD identification.
Compounds with mechanisms of action that are independent of ion channel modulation may someday find a place in the management of drug-resistant epilepsy. We therefore tested the acute anticonvulsant efficacy of a serotonergic mechanism with FXT. 8 One limitation of this present study was that the dose tested did not interrogate a full dose range and any conclusions concerning the potential clinical utility in drug-resistant individuals would be premature. Nonetheless, we selected a dose of FXT that had demonstrated acute anticonvulsant efficacy in the mouse MES threshold test. 32 We did not detect physiologically relevant reductions in MSS with this dose of FXT administered to VEH-kindled mice. However, this dose of FXT exacerbated MSS in LTG-resistant CKM. It has been hypothesized that in addition to effects on serotonin levels, FXT may also exert anticonvulsant activity through an increase in c-aminobutyric acid (GABA) A receptor activity and/or inhibitory effects on sodium channels. 40 FXT presently worsened the seizure phenotype of LTG-resistant CKM to a degree only observed in the presence of other sodium channel modulators (eg, CBZ, PHT). Whether other agents with a serotonin-specific mechanism differentially modulate MSS in the LTG-resistant CKM remains to be defined. Anti-inflammatory agents are also hypothesized to modify seizure presentation. MIN possess acute anticonvulsant efficacy in the mouse 6 Hz model (median effective dose of 170 mg/kg, ip). 31 We chose to forgo any dose-response with MIN because kindled rodents are more sensitive than na€ ıve rodents to adverse drug effects 30 and we have also previously reported mortality associated with MIN in mice with a history of seizures. 27 Pilot studies with LTG-resistant CKM resulted in mortality with MIN doses >100 mg/ kg (data not shown), a dose well below that which is motor-impairing in naive mice (250 mg/kg 31 ). CXB was also without effect at the doses tested. Whether other compounds that engage alternative anti-inflammatory mechanisms, such as interleukin-6 [IL-6] or tumer necrosis factor a [TNF-a], could be effective in the LTG-resistant CKM will necessarily away further study. The LTG-resistant CKM is a useful screening tool in the search for novel therapeutics for pharmacoresistant epilepsy. Although this study did not define the mechanisms underlying pharmacoresistance, this LTG-resistant CKM model may be useful to better understand the processes that promote ASD resistance and the pharmacological effectiveness of investigational ASDs, especially after an approved ASD (ie, LTG) has "failed" to control seizures. There is insufficient preclinical evidence to understand why there is variability in seizure control in otherwise similar seizure phenotypes. The LTG-resistant CKM provides a unique approach to interrogate how ASD selection alone may modify future disease course. LTG monotherapy in both rats 18 and now mice (present study) during epileptogenesis leads to a significant divergence in subsequent ASD efficacy. The finding that early therapeutic intervention may dramatically impact the success of subsequent treatments is an important observation that has now been replicated in 2 independent models and species; LTG-resistant CKM provide an experimental platform for dissecting the mechanism underlying this phenomenon. Future studies using clinically relevant dosing protocols or alternative ASDs may provide additional insight into the nature of pharmacoresistance. Such studies may help to define a strategy that will reduce the incidence of pharmacoresistant epilepsy.
